The Clorox Company $CLX Shares Bought by Vest Financial LLC

Vest Financial LLC lifted its position in The Clorox Company (NYSE:CLX) by 13.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 383,962 shares of the company’s stock after acquiring an additional 45,773 shares during the quarter. Vest Financial LLC owned 0.31% of Clorox worth $46,102,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. American National Bank & Trust increased its holdings in shares of Clorox by 69.5% in the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock valued at $26,000 after acquiring an additional 89 shares during the last quarter. Ransom Advisory Ltd bought a new stake in shares of Clorox in the 1st quarter valued at approximately $35,000. GW&K Investment Management LLC increased its holdings in shares of Clorox by 239.1% in the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock valued at $43,000 after acquiring an additional 208 shares during the last quarter. Roble Belko & Company Inc increased its holdings in shares of Clorox by 140.7% in the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock valued at $53,000 after acquiring an additional 211 shares during the last quarter. Finally, IMA Advisory Services Inc. bought a new stake in shares of Clorox in the 1st quarter valued at approximately $58,000. 78.53% of the stock is currently owned by institutional investors.

Clorox Stock Performance

Shares of CLX opened at $120.14 on Monday. The company has a market cap of $14.63 billion, a price-to-earnings ratio of 18.43, a price-to-earnings-growth ratio of 0.98 and a beta of 0.52. The firm has a fifty day moving average of $122.21 and a 200-day moving average of $128.57. The Clorox Company has a 1 year low of $116.53 and a 1 year high of $171.37. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.63. The business had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, equities analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be given a $1.24 dividend. The ex-dividend date is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.1%. Clorox’s payout ratio is 76.07%.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.57% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on CLX shares. Zacks Research upgraded Clorox from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. UBS Group lowered their price target on Clorox from $134.00 to $128.00 and set a “neutral” rating for the company in a report on Wednesday. Citigroup lowered their price target on Clorox from $135.00 to $130.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Barclays lowered their price objective on Clorox from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Tuesday, September 30th. Finally, Jefferies Financial Group cut their target price on Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. One investment analyst has rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Clorox currently has an average rating of “Reduce” and an average target price of $131.92.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.